Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Addex Therapeutics ( (CH:ADXN) ) has provided an announcement.
Addex Therapeutics announced it will release its Half-Year and Second Quarter 2025 financial results on September 30, 2025, followed by a conference call on October 1, 2025, to discuss the results and provide a business update. This announcement is significant for stakeholders as it will provide insights into the company’s financial health and progress in its product pipeline, potentially impacting its market positioning and future strategies.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, and the company is also advancing programs for substance use disorders, chronic cough, and various neurocognitive disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol ‘ADXN’.
Average Trading Volume: 444,053
Current Market Cap: CHF12.5M
Find detailed analytics on ADXN stock on TipRanks’ Stock Analysis page.